Please assess the completion status of the following clinical trial:

Trial Title: Adjuvant Chemotherapy for High Risk Uterine Leiomyosarcoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* ≥ 18 years of age~* high risk uterine LMS, FIGO stage I or II~* pathology review of LMS high grade and /or mitotic rate greater than or equal to 5 mitoses/10 hpf~* no longer than 12 weeks from surgical resection of cancer~* no evidence of residual disease~* ECOG 0 or 1~* ANC ≥ 1,500, hemoglobin ≥ 8.0, platelets ≥100,000~* creatinine ≤ 1.5 x institutional upper limits of normal~* adequate liver function~* neuropathy (sensory and motor) ≤ CTC grade 1~* negative pregnancy test~* signed consent~Exclusion Criteria:~* patients with other invasive malignancies~* prior therapy with gemcitabine or docetaxel or doxorubicin~* hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 80~* women who are breast feeding~* cardiac ejection fraction \<50%~* prior pelvic irradiation~* treatment with hormone replacement or anti-hormonal agents or other cytotoxic agents

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- gemcitabine/docetaxel then doxorubicin (Type: OTHER): Gemcitabine 900 mg/m2 IV over 90 minutes days 1 and 8 Docetaxel 75 mg/m2 IV day 8 (pre-medication dexamethasone 4-8 mg p.o. bid for 3 days, starting 12-24 hours prior to docetaxel). Doxorubicin 60 mg/m2 IVP every 21 days for 4 cycles (recommend use of central venous catheter access).

Based on this trial design, predict the completion outcome and termination type (if applicable).